type here...
type here...
START FREE TRIAL

M&A

Technology & AIHealthcareM&AConsumer & RetailEnergyMiscellaneous

This “Broken” Biotech Just Forced Wall Street To Blink

M&A Ishan Majumdar -
Apellis Pharmaceuticals (NASDAQ:APLS) did not suddenly discover a miracle on Tuesday. What changed was the price investors were willing to pay for the same...

This Widely Held “Defensive” Stock Is Now Tied To A Large Scale Merger

M&A Ishan Majumdar -
For years, McCormick (NYSE:MKC) has been framed as one of those dependable staples names investors can tuck away and revisit later: a focused flavor...
spot_imgspot_img

Did Mastercard Just Buy Growth, Or A REAL New Rail With Hidden Execution Risk?

M&A Ishan Majumdar -
BVNK’s platform lets businesses send, receive, store, and convert digital currencies through one system. That sounds simple, but the...

Did Apple’s MotionVFX Acquisition Just DEEPEN Its Creator Ecosystem Moat?

M&A Ishan Majumdar -
Apple (NASDAQ:AAPL) has been busy giving investors plenty to chew on. The company just posted a record quarter, with...

Is Meta’s Moltbook Deal About Social Media … Or The Future Of AI Agents?

M&A Ishan Majumdar -
Recent developments around Meta Platforms (NASDAQ:META) suggest the company is continuing its aggressive push into artificial intelligence infrastructure and...

Agilent’s $950M Biocare Acquisition Could Unlock A Powerful Recurring Revenue Flywheel

M&A Ishan Majumdar -
The diagnostics and life sciences equipment industry rarely stands still. But recent developments around Agilent Technologies (NYSE:A) have drawn...

Salesforce Just Bought Momentum — But The REAL Play Is Workflow Control!

M&A Ishan M. -
It has been a busy stretch for Salesforce (NYSE:CRM). Fresh off a strong fiscal third quarter, the company is...

Is Eli Lilly’s Orna Acquisition About RNA Or Something MUCH BIGGER?

M&A Ishan Majumdar -
Eli Lilly’s move to acquire Orna Therapeutics landed quietly, framed as another pipeline add-on in a year already defined...
Load more

This “Broken” Biotech Just Forced Wall Street To Blink

M&A Ishan Majumdar -
Apellis Pharmaceuticals (NASDAQ:APLS) did not suddenly discover a miracle on Tuesday. What changed was the price investors were willing...

This Widely Held “Defensive” Stock Is Now Tied To A Large Scale Merger

M&A Ishan Majumdar -
For years, McCormick (NYSE:MKC) has been framed as one of those dependable staples names investors can tuck away and...

Did Mastercard Just Buy Growth, Or A REAL New Rail With Hidden Execution Risk?

M&A Ishan Majumdar -
BVNK’s platform lets businesses send, receive, store, and convert digital currencies through one system. That sounds simple, but the...

Did Apple’s MotionVFX Acquisition Just DEEPEN Its Creator Ecosystem Moat?

M&A Ishan Majumdar -
Apple (NASDAQ:AAPL) has been busy giving investors plenty to chew on. The company just posted a record quarter, with...

Is Meta’s Moltbook Deal About Social Media … Or The Future Of AI Agents?

M&A Ishan Majumdar -
Recent developments around Meta Platforms (NASDAQ:META) suggest the company is continuing its aggressive push into artificial intelligence infrastructure and...

Agilent’s $950M Biocare Acquisition Could Unlock A Powerful Recurring Revenue Flywheel

M&A Ishan Majumdar -
The diagnostics and life sciences equipment industry rarely stands still. But recent developments around Agilent Technologies (NYSE:A) have drawn...

Salesforce Just Bought Momentum — But The REAL Play Is Workflow Control!

M&A Ishan M. -
It has been a busy stretch for Salesforce (NYSE:CRM). Fresh off a strong fiscal third quarter, the company is...

Is Eli Lilly’s Orna Acquisition About RNA Or Something MUCH BIGGER?

M&A Ishan Majumdar -
Eli Lilly’s move to acquire Orna Therapeutics landed quietly, framed as another pipeline add-on in a year already defined...

Is Apple Outflanking Meta With This Q.AI Move?

M&A Ishan Majumdar -
Apple acquired Israeli startup Q.AI for close to $2B, locking down patents around “facial skin micro movements” that enable...

Ascendis Pharma Becomes M&A Target Again—European Suitors In Play?

M&A Ishan Majumdar -
Ascendis Pharma (NASDAQ:ASND) has suddenly become one of the hottest tickers in biotech circles after its shares surged 7.5%...

BioMarin Amicus Acquisition: A $4.8 Billion Bet on Rare Disease Domination

Healthcare Ishan Majumdar -
BioMarin Pharmaceutical (NASDAQ:BMRN) just made its boldest move in years—unveiling a $4.8 billion all-cash acquisition of Amicus Therapeutics. The...

APi Group CertaSite Acquisition Sparks Investor Debate

Industrials Ishan Majumdar -
In a season crowded with earnings calls, margin debates, and cautious optimism, one headline stood out: APi Group (NYSE:APG)...
Load more

Baptista Research is a financial research house focused on the U.S. markets. We cover the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms.

Company

Headlines

This “Broken” Biotech Just Forced Wall Street To Blink

0
Apellis Pharmaceuticals (NASDAQ:APLS) did not suddenly discover a miracle...

Tesla Is Quietly Killing Its Own Cars—& What Comes Next Could Be MUCH BIGGER

0
For years, most investors have approached Tesla as an...

This Medical Device Stock Just Got CRUSHED On One Hidden Number; Did Wall Street Misread It?

0
Boston Scientific (NYSE:BSX) spent the weekend putting forward what...

This Widely Held “Defensive” Stock Is Now Tied To A Large Scale Merger

0
For years, McCormick (NYSE:MKC) has been framed as one...

Newsletter

Get important news delivered directly to your inbox and stay connected!

Copyright © 2026 Baptista Research. All rights reserved.